Ramipril in High-Risk Patients With COVID-19.
Aged
Aged, 80 and over
Angiotensin-Converting Enzyme Inhibitors
/ adverse effects
Betacoronavirus
COVID-19
Coronavirus Infections
/ chemically induced
Female
Humans
Male
Pandemics
Pneumonia, Viral
/ chemically induced
Ramipril
/ adverse effects
Randomized Controlled Trials as Topic
Risk Factors
SARS-CoV-2
Spain
/ epidemiology
COVID-19
SARS-CoV-2
renin-angiotensin
transcatheter aortic valve replacement
Journal
Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365
Informations de publication
Date de publication:
21 07 2020
21 07 2020
Historique:
received:
27
04
2020
revised:
20
05
2020
accepted:
20
05
2020
pubmed:
30
5
2020
medline:
25
7
2020
entrez:
30
5
2020
Statut:
ppublish
Résumé
Coronavirus disease-2019 (COVID-19) is caused by severe acute respiratory-syndrome coronavirus-2 that interfaces with the renin-angiotensin-aldosterone system (RAAS) through angiotensin-converting enzyme 2. This interaction has been proposed as a potential risk factor in patients treated with RAAS inhibitors. This study analyzed whether RAAS inhibitors modify the risk for COVID-19. The RASTAVI (Renin-Angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation) trial is an ongoing randomized clinical trial randomly allocating subjects to ramipril or control groups after successful transcatheter aortic valve replacement at 14 centers in Spain. A non-pre-specified interim analysis was performed to evaluate ramipril's impact on COVID-19 risk in this vulnerable population. As of April 1, 2020, 102 patients (50 in the ramipril group and 52 in the control group) were included in the trial. Mean age was 82.3 ± 6.1 years, 56.9% of the participants were male. Median time of ramipril treatment was 6 months (interquartile range: 2.9 to 11.4 months). Eleven patients (10.8%) have been diagnosed with COVID-19 (6 in control group and 5 receiving ramipril; hazard ratio: 1.150; 95% confidence interval: 0.351 to 3.768). The risk of COVID-19 was increased in older patients (p = 0.019) and those with atrial fibrillation (p = 0.066), lower hematocrit (p = 0.084), and more comorbidities according to Society of Thoracic Surgeons score (p = 0.065). Admission and oxygen supply was required in 4.9% of patients (2 in the ramipril group and 3 in the control group), and 4 of them died (2 in each randomized group). A higher body mass index was the only factor increasing the mortality rate (p = 0.039). In a high-risk population of older patients with cardiovascular disease, randomization to ramipril had no impact on the incidence or severity of COVID-19. This analysis supports the maintenance of RAAS inhibitor treatment during the COVID-19 crisis. (Renin-Angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation [RASTAVI]; NCT03201185).
Sections du résumé
BACKGROUND
Coronavirus disease-2019 (COVID-19) is caused by severe acute respiratory-syndrome coronavirus-2 that interfaces with the renin-angiotensin-aldosterone system (RAAS) through angiotensin-converting enzyme 2. This interaction has been proposed as a potential risk factor in patients treated with RAAS inhibitors.
OBJECTIVES
This study analyzed whether RAAS inhibitors modify the risk for COVID-19.
METHODS
The RASTAVI (Renin-Angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation) trial is an ongoing randomized clinical trial randomly allocating subjects to ramipril or control groups after successful transcatheter aortic valve replacement at 14 centers in Spain. A non-pre-specified interim analysis was performed to evaluate ramipril's impact on COVID-19 risk in this vulnerable population.
RESULTS
As of April 1, 2020, 102 patients (50 in the ramipril group and 52 in the control group) were included in the trial. Mean age was 82.3 ± 6.1 years, 56.9% of the participants were male. Median time of ramipril treatment was 6 months (interquartile range: 2.9 to 11.4 months). Eleven patients (10.8%) have been diagnosed with COVID-19 (6 in control group and 5 receiving ramipril; hazard ratio: 1.150; 95% confidence interval: 0.351 to 3.768). The risk of COVID-19 was increased in older patients (p = 0.019) and those with atrial fibrillation (p = 0.066), lower hematocrit (p = 0.084), and more comorbidities according to Society of Thoracic Surgeons score (p = 0.065). Admission and oxygen supply was required in 4.9% of patients (2 in the ramipril group and 3 in the control group), and 4 of them died (2 in each randomized group). A higher body mass index was the only factor increasing the mortality rate (p = 0.039).
CONCLUSIONS
In a high-risk population of older patients with cardiovascular disease, randomization to ramipril had no impact on the incidence or severity of COVID-19. This analysis supports the maintenance of RAAS inhibitor treatment during the COVID-19 crisis. (Renin-Angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation [RASTAVI]; NCT03201185).
Identifiants
pubmed: 32470515
pii: S0735-1097(20)35395-X
doi: 10.1016/j.jacc.2020.05.040
pmc: PMC7250557
pii:
doi:
Substances chimiques
Angiotensin-Converting Enzyme Inhibitors
0
Ramipril
L35JN3I7SJ
Banques de données
ClinicalTrials.gov
['NCT03201185']
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
268-276Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Références
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
J Travel Med. 2020 May 18;27(3):
pubmed: 32186711
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Hypertension. 2020 Jun;75(6):1382-1385
pubmed: 32208987
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
Nature. 2005 Jul 7;436(7047):112-6
pubmed: 16001071
Lancet. 2003 Oct 25;362(9393):1353-8
pubmed: 14585636
Internist (Berl). 2019 Nov;60(11):1136-1145
pubmed: 31455974
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
J Hypertens. 2020 May;38(5):781-782
pubmed: 32195824
N Engl J Med. 2020 Apr 23;382(17):1653-1659
pubmed: 32227760
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464
pubmed: 32298251
BMJ Open. 2018 Feb 13;8(2):e020255
pubmed: 29440218
Emerg Microbes Infect. 2020 Dec;9(1):757-760
pubmed: 32228222
Circulation. 2020 Aug 4;142(5):426-428
pubmed: 32213097
N Engl J Med. 2012 Nov 8;367(19):1814-20
pubmed: 23075143
Nature. 2003 Nov 27;426(6965):450-4
pubmed: 14647384
N Engl J Med. 2003 May 15;348(20):1967-76
pubmed: 12690091
J Am Heart Assoc. 2020 Apr 7;9(7):e016509
pubmed: 32233753
Circulation. 2010 Aug 17;122(7):717-28, 18 p following 728
pubmed: 20679547
Eur Heart J. 2020 May 14;41(19):1801-1803
pubmed: 32196087
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Obesity (Silver Spring). 2020 Jun;28(6):1005
pubmed: 32237206
J Am Coll Cardiol. 2019 Aug 6;74(5):631-641
pubmed: 31370954
Circulation. 2005 May 24;111(20):2605-10
pubmed: 15897343
J Card Fail. 2020 May;26(5):370
pubmed: 32439095
JAMA. 2020 May 12;323(18):1769-1770
pubmed: 32208485
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Lancet Respir Med. 2020 Apr;8(4):e21
pubmed: 32171062
Endocrine. 2020 Apr;68(1):2-5
pubmed: 32279224